Dr. Sarah Leary, MD
Claim this profileSeattle Children's Hospital
Expert in Brain Tumor
Expert in Tumors
74 reported clinical trials
129 drugs studied
About Sarah Leary, MD
Education:
- Earned an MD (Doctor of Medicine).
- Holds an MS (Master of Science).
Experience:
- Since August 2009, serves as Attending Physician and Medical Director of the Pediatric Brain Tumor Program at Seattle Children's Hospital.
- Professor in the Department of Pediatrics at the University of Washington School of Medicine.
- Medical Director of Clinical Research at the Ben Towne Center for Childhood Cancer Research.
- Actively involved in national and international pediatric brain tumor research and data sharing initiatives.
- Recognized as Seattle's Top Doctor in 2022 by Seattle Magazine.
Area of expertise
1Brain Tumor
Global LeaderStage I
Stage II
Stage IV
2Tumors
Global LeaderStage I
Stage IV
Stage II
Affiliated Hospitals
Clinical Trials Sarah Leary, MD is currently running
Genetic Testing-Directed Therapy
for Pediatric Cancer
This Pediatric MATCH screening and multi-sub-study phase II trial studies how well treatment that is directed by genetic testing works in pediatric patients with solid tumors, non-Hodgkin lymphomas, or histiocytic disorders that have progressed following at least one line of standard systemic therapy and/or for which no standard treatment exists that has been shown to prolong survival. Genetic tests look at the unique genetic material (genes) of patients' tumor cells. Patients with genetic changes or abnormalities (mutations) may benefit more from treatment which targets their tumor's particular genetic mutation, and may help doctors plan better treatment for patients with solid tumors or non-Hodgkin lymphomas.
Recruiting1 award Phase 214 criteria
Selumetinib vs. Chemotherapy
for Brain Cancer
This trial is comparing a new drug, selumetinib, with standard chemotherapy to treat patients with a specific type of brain tumor. The patients do not have a certain genetic mutation and are not affected by a genetic disorder. Selumetinib works by blocking enzymes needed for tumor growth, while the standard drugs kill or stop tumor cells from dividing.
Recruiting2 awards Phase 3
More about Sarah Leary, MD
Clinical Trial Related7 years of experience running clinical trials · Led 74 trials as a Principal Investigator · 28 Active Clinical TrialsTreatments Sarah Leary, MD has experience with
- Cyclophosphamide
- Radiation Therapy
- Etoposide
- Doxorubicin Hydrochloride
- Nivolumab
- Vincristine Sulfate
Breakdown of trials Sarah Leary, MD has run
Brain Tumor
Tumors
Lymphoma
Neuroblastoma
Other Doctors you might be interested in
Frequently asked questions
Do I need insurance to participate in a trial?
Almost all clinical trials will cover the cost of the ‘trial drug’ — so no insurance is required for this. For trials where this trial drug is given alongside an already-approved medication, there may be a cost (which your insurance would normally cover).
What does Sarah Leary, MD specialize in?
Sarah Leary, MD focuses on Brain Tumor and Tumors. In particular, much of their work with Brain Tumor has involved Stage I patients, or patients who are Stage II.
Is Sarah Leary, MD currently recruiting for clinical trials?
Yes, Sarah Leary, MD is currently recruiting for 26 clinical trials in Seattle Washington. If you're interested in participating, you should apply.
Are there any treatments that Sarah Leary, MD has studied deeply?
Yes, Sarah Leary, MD has studied treatments such as Cyclophosphamide, Radiation Therapy, Etoposide.
What is the best way to schedule an appointment with Sarah Leary, MD?
Apply for one of the trials that Sarah Leary, MD is conducting.
What is the office address of Sarah Leary, MD?
The office of Sarah Leary, MD is located at: Seattle Children's Hospital, Seattle, Washington 98105 United States. This is the address for their practice at the Seattle Children's Hospital.
Is there any support for travel costs?
The coverage of travel expenses can vary greatly between different clinical trials. Please see more financial detail in the trials you’re interested to apply.